About the Event
MAIA Biotechnology [NYSE: MAIA] just reported positive topline safety data from its Phase 2 trial for THIO in advanced Non-Small Cell Lung Cancer.
In preclinical studies THIO was shown to kill 70-90% of the cancer cells in just 24-72 hours.
Join our webinar with CEO, Vlad Vitoc, to hear more details about MAIA’s path to market and why the FDA has awarded the platform two Orphan Drug Designations.